Previous close | 2,273.50 |
Open | 2,250.50 |
Bid | 2,289.00 x 0 |
Ask | 2,295.00 x 0 |
Day's range | 2,249.00 - 2,297.00 |
52-week range | 2,232.50 - 2,966.50 |
Volume | |
Avg. volume | 2,225,006 |
Market cap | 1.077T |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 8.60 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 80.00 (3.52%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L. Hoerter, "Deciphera") today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer follow
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that in order to accelerate the open innovation, it has increased its investment pool from US$100 million to US$200 million to continue strategic investment in Ono Venture Investment Fund I, L.P. ("OVI FI"), which was established as a corporate venture capital fund in CA, USA in May 2020.